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Background: Bovine papillomaviruses (BPVs) types 1 and 2 are the only known papillomaviruses able to jump the
species. In fact, BPVs 1/2 induce neoplasia in their natural bovine host but infection is also associated to neoplastic
skin lesions in equids termed sarcoids. The equine sarcoid is considered to be the most common equine cutaneous
tumour worldwide for which no effective therapy is available. Very little is known about the molecular mechanisms
underlying tumourigenesis, although genes contributing to sarcoid development have been identified. Several
studies associate the development of cancer to the loss of function of a number of oncosuppressor genes. In this
study the putative role of O6-methylguanine-DNA methyltrasferase (MGMT) was investigated for sarcoids. The
expression of the oncosuppressor protein was assessed in normal and sarcoid cells and tissues. In addition,
the DNA methylation profile was analysed to assess the role of epigenetic mechanism in regulation of MGMT
expression.
Results: A group of 15 equine sarcoids and two primary sarcoid cell lines (fibroblasts) were analyzed for the
expression of MGMT protein by immunohistochemistry, immunofluorescence and Western blotting techniques.
The sarcoid cell line EqSO4b and the tumour samples showed a reduction or absence of MGMT expression. To
investigate the causes of deregulated MGMT expression, ten samples were analyzed for the DNA methylation
profile of the CpG island associated to the MGMT promoter. The analysis of 73 CpGs encompassing the region of
interest showed in 1 out of 10 (10%) sarcoids a pronouncedly altered methylation profile when compared to the
control epidermal sample. Similarily the EqSO4b cell line showed an altered MGMT methylation pattern in
comparison to normal fibroblasts.
Conclusion: As previously demonstrated for the oncosuppressor gene FHIT, analysis of MGMT expression in sarcoid
tissues and a sarcoid-derived fibroblast cell line further suggests that oncosuppressor silencing may be also
involved in BPV-induced equine tumours. Abnormal DNA methylation seems to be one of the possible molecular
mechanisms involved in the alteration of MGMT expression. Further studies are required to address other basic
molecular mechanisms involved in reduced MGMT expression. This study underlines the possible role of DNA
methylation in oncosuppressor inactivation in equine sarcoids.
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Sarcoids are locally invasive skin tumours of equids and
are considered to be the most common equine cutane-
ous neoplasm worldwide [1]. Macroscopically, sarcoids
vary and six different clinical types are recognized: occult,
verrucous, nodular, fibroblastic, mixed and malevolent [2].
They are histologically characterized by disorganized der-
mal proliferation of spindle-shaped fibroblasts that form
whorls and by epidermal hyperplasia, hyperkeratosis, and
rete peg formation [3]. The tumours can occur anywhere
on animal’s body; however they often arise in areas of
previous injury or scarring; additionally, they very rarely
regress, more often persist and can be locally aggressive.
Currently, there is no effective therapy available for
sarcoids [4].
Many reports in the literature have shown that BPV
type 1 and less commonly type 2 are involved in the
pathogenesis of sarcoids. Recent studies have highlighted
the role of the BPV oncogenes E5 and E7 in the carcino-
genesis [5-7]. However, little is known regarding the mo-
lecular mechanisms underlying sarcoid tumourigenesis
and only few genes contributing to the development of
this neoplastic disease have been identified so far [8].
Several studies associate the development of cancer to
the loss of function of a number of oncosuppressor
genes. In a recent work (Strazzullo et al., 2012) we have
provided evidence for an altered expression of the FHIT
protein in sarcoid tissues and derived cell lines. FHIT is
the first oncosuppressor gene whose aberrant expression
has been associated to equine sarcoids whereas it is fre-
quently altered in human tumours associated to papillo-
mavirus infection.
MGMT is another oncosuppressor gene often inacti-
vated in human PV-induced tumours. This gene, also
called O6-alkylguanine-DNA alkyltransferase, encodes
for a DNA repair protein that removes mutagenic and
cytotoxic adducts from O6-guanine in DNA [9]. Alkyl-
ation of DNA at the O6 position of guanine is an import-
ant step in the formation of mutations in cancer,
primarily due to the tendency of the O6–methylguanine
to pair with thymine during replication, resulting in the
conversion of guanine-cytosine to adenine-thymine pairs
in DNA [10]. Moreover, the O6 –methylguanine adducts
crosslink with the opposite cytosine residues, blocking
DNA replication [11]. MGMT is able to protect cells from
such biological processes, resulting in the direct restor-
ation of the normal guanine structure [12]. The alkylated
MGMT becomes detached from DNA and is degraded
through ubiquitination-dependent proteolysis [13].
The expression of the MGMT protein is decreased in a
wide spectrum of human tumours due to several genetic
mechanisms and as a consequence of the hypermethylation
of the promoter region [14]. In some human cancers, such
as gliomas, inactivation of MGMT gene correlates with abetter prognosis as this condition allows a better respon-
siveness to therapy with alkylating agents [15].
MGMT is a well-known target for methylation inacti-
vation in HPV-induced cancer [16] but its role in
BPV-induced cancer has not been investigated so far.
DNA methylation is a frequent epigenetic event in many
human cancers. Many studies have pointed out that pro-
moter methylation of tumour suppressor genes is linked
with HPV-induced cervical carcinogenesis [16,17].
Whilst alterations in MGMT expression have been
reported for several human cancers comprising those
induced by HPV, a putative role of this gene and of epi-
genetic alteration, to the best of our knowledge, has
never been investigated in veterinary oncology [14,15,18].
In order to gain new insights into possible mechan-
isms underlying BPV-mediated carcinogenesis, we inves-
tigated the status of MGMT protein expression in
equine sarcoid cell lines and sarcoid tumours. The
samples showing significantly reduced MGMT protein
expression were further analyzed for the DNA methy-
lation status of equine MGMT CpG island spanning
the predicted 50UTR.Results
MGMT protein expression in sarcoids and cell lines
To investigate the potential oncosuppressor involvement
in equine sarcoid carcinogenesis, we analyzed immuno-
histochemically 10 out of 15 tumour samples for MGMT
expression. Negative staining for MGMT protein was
observed in 5 out of 10 cases (50%) (Figure 1A); 2 sarcoid
samples (20%) displayed very weak immunostaining
signal in only few areas of the lesion (data not shown).
The remaining sarcoid samples (30%), showed a very faint
intracytoplasmic immunostaining signal for MGMT
throughout the lesion (Figure 1B).
Normal fibroblasts derived from healthy horses dis-
played nuclear and cytoplasmic staining pattern for the
MGMT protein. Additionally, cells from the different
skin layers also stained positive (Figure 1C). Human ton-
sil tissue section used as positive control showed positive
immunostaining (Figure 1D).
We also analyzed the equine sarcoid derived cell lines
for the expression of MGMT protein. By indirect im-
munofluorescence, distinct staining was detected in the
E-Derm and EqSO1a sarcoid cell lines. In E-Derm the
staining pattern was diffuse and the immunofluorecence
signal was detected within the cytosol as well as in the
nuclei of mitotic cells (Figure 2A). In EqSO1a the im-
munofluorescence signal was detected only within the
cytosol and the staining pattern was diffuse (Figure 2B).
IF staining of the sarcoid cell line EqSO4b yielded very
weak and hardly perceptible signal for MGMT protein
(Figure 2C).
Figure 1 Illustration of representative immunohistochemistry in equine normal skin and sarcoid lesions. A) MGMT negative
immunoreactivity in a sarcoid sample. Neoplastic fibroblasts are negative for MGMT staining. Strepatavidin-biotin peroxidase method.
Mayer’s haematoxylin nuclear counterstaining. x 240. B) Sarcoid sample showing very weak MGMT immunoreactivity. Some fibroblasts from the
neoplastic tissue show a very faint cytoplasmic immunostaining for MGMT. Strepatavidin-biotin peroxidase method. Mayer’s haematoxylin nuclear
counterstaining. IHC. x 240. C) MGMT staining of normal equine skin. Normal fibroblasts from derma displayed nuclear and cytoplasmic staining
for MGMT. The different epidermal layers are also stained. Strepatavidin-biotin peroxidase method. Mayer’s haematoxylin nuclear counterstaining.
IHC. x 240. D) Human tonsil tissue section. Epithelial cells show positive MGMT immunostaining. Strepatavidin-biotin peroxidase method.
Mayer’s haematoxylin nuclear counterstaining. IHC. x 120.
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MGMT protein expression, 5 sarcoid samples, which
were available for biochemical analysis and skin from a
healthy horse were analysed by Western blot. Cell lines
were also analyzed. The anti-MGMT antibody yielded a
band of the expected molecular weight in the neoplastic
tissues, normal skin and all fibroblast cell lines. An in-
crease in the amount of MGMT protein level in normal
skin versus tumour samples was observed (Figure 3A).
In addition, MGMT expression levels were lower in
EqSO4b sarcoid cell line, whilst EqSO1a showed similarFigure 2 Down-regulated MGMT protein expression in equine sarcoid
protein in normal equine fibroblasts and sarcoid fibroblasts, assessed by co
cytoplasmic staining for MGMT. Nuclei of mitotic cells express MGMT (inser
cytoplasmic staining. x120. C) Fully transformed fibroblasts EqSO4b show aMGMT expression when compared to E-Derm cells
(Figure 3B).
Equine MGMT CpG island and DNA methylation analysis
in sarcoid tissues and cell lines
The 10 sarcoids that stained biochemically or immuno-
histochemically negative or very weakly positive for
MGMT protein expression, were analyzed for the potential
involvement of epigenetic mechanisms in the abnormal
expression of this oncosuppressor. To this aim, DNA
methylation profile of the CpG island associated to thefibroblasts. Immunofluorescence-mediated detection of MGMT
nfocal microscopy. A) Normal fibroblasts cell line E-Derm shows
t).x120. B) Fully transformed fibroblasts EqSO1a show a faint
very faint cytoplasmic staining. x120.
Figure 3 MGMT molecular expression in sarcoid tissues and sarcoid derived cell lines. A) Western blotting showing the reduced protein
expression of MGMT in sarcoid tissues (S1-S5) in comparison with a normal skin sample (N). B) Western blotting showing the reduced in vitro
protein expression of MGMT in 2 sarcoid cell lines (EqSO1a, EqSO4b) in comparison with normal fibroblast cell line (E-Derm). The lower blot
shows actin expression to demonstrate the same amount of protein loaded onto the gel.
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was performed also for sarcoid-derived cell lines EqSO1a
and EqSO4b.
The only equine MGMT sequence available in Gen-
Bank, is the predicted coding sequence and a partial
50 UTR region [XM_001488425.3]. To obtain the horse
specific sequence of the upstream region corresponding
to the human, murine and bovine CpG island, the cds
sequence was used to query the UCSC database.
Through the BLAT algorithm and using the Horse Sep.
2007 (Broad/equCab2) Assembly, the MGMT upstream
region was obtained (about 800 bp). An unknown region
we localized in the UCSC sequence was identified by
PCR amplification and subsequent bidirectional sequen-
cing (see material and methods). The CpGplot analysis
revealed a CpG island of about 635 bp. A region of
573 bp, including 73 CpGs, was subjected to sodium
bisulfite sequencing. Figure 4A shows a not in scale
scheme of the 50 region of the equine MGMT locus, and
the relative position of the predicted CpG island (shaded)
as reconstructed according to the information obtained
from UCSC and NCBI databases.
The DNA extracted from the sarcoid samples and
from a BPV negative normal skin sample, was converted
by sodium bisulfite. Figure 4B on the top, shows the
CpG island prediction obtained through the MethPrimer
algorithm (http://www.urogene.org/methprimer/index1.
html) and the position of the specific primers obtained
using the same algorithm. The region of interest was
amplified, cloned and sequenced. For each samples at
least 10 clones were sequenced. One sarcoid sample
showed a clear difference in the DNA methylation con-
tent compared to the normal control. A similar analysis
was performed also for the sarcoid cell lines, EqSO1a
and EqSO4b compared to the E-Derm fibroblast cell
lines. Also the EqSO4b showed a different methylation
pattern when compared to the normal skin derived cell
line E-Derm, similarly to that observed in the positive
sarcoid sample. In the lower part of Figure 4B, the pos-
ition of methylated and unmethylated cytosines in the
different clones sequenced is shown for normal andsarcoid tissue and for the E-Derm cell line and sarcoid
cell line EqSO4b.
Discussion
DNA methylation is a frequent epigenetic event in many
human cancers [19,20]. The transcriptional silencing by
the hypermethylation of CpG islands in the promoter re-
gion, is a well-known common mechanism for the in-
activation of tumour suppressor genes in human
malignancies [21,22]. In an ongoing study aiming at in-
vestigating the possible epigenetic changes of oncosup-
pressor genes involved in sarcoid carcinogenesis, we
have recently demonstrated a noticeable alteration of ex-
pression of the FHIT protein (Strazzullo et al., 2012),
which encouraged the investigation of the role of other
oncosuppressor genes and of their regulative mechan-
isms in sarcoid molecular pathology. Since many lines of
evidence support the association between HPV infection
and MGMT expression alteration [23,24], we analyzed
the role of the MGMT gene.
In this study we investigated the expression of the
MGMT protein within a normal fibroblast cell line
(E-Derm) and the fully transformed sarcoid fibroblast
lines explanted from an equine sarcoid tumour (EqSO1a
and EqSO4b), as well as the pattern of expression in
normal skin and sarcoid tissues. Our data indicate, for
the first time, a noticeable reduction and or absence of
MGMT protein in naturally occurring sarcoid tumours
as well as in sarcoid derived cell lines.
Sarcoids may exist as six different clinical types [2], we
have not found a correlation between down-regulation
of MGMT expression and clinical appearance, suggest-
ing the existence of a common mechanism underlying
the reduction of protein expression that acts early during
the development of equine sarcoids. Our results are in
agreement with several previous studies indicating that
the loss and or reduced expression of MGMT is fre-
quent in a variety of tumours [25], particularly in HPV-
induced cervical lesions [26-28]. It is possible that
decrease ofMGMT protein expression is a commonmech-
anism of cancer development among different species.
Figure 4 Horse MGMT locus organization and schematic representation of the sodium bisulfite analysis. A) A mere schematic, not in
scale, presentation of the 5'UTR of the MGMT genomic locus on chromosome 1 is shown; the shaded box indicates the position of the CpG
island with respect to the exon 1 and exon 2. The ATG position is also reported. The dotted line indicates the not defined boundary between
Exon 1 and regulative region. B) In the top are summerised the Methprimer predicted CpG island and the position of primers used for nested
PCR. In the lower part, circles indicate methylation status: filled circles, methylated CpGs; open circles: unmethylated CpGs. Each row of circles
corresponds to one clone. For each sample 73 CpGs were analysed; the column on the left of each sample are referred to the number of
indipendent clones sequenced. C, control tissue; S2, sarcoid sample; E, E-Derm cell line; 4b, Sarcoid cell line EqSO4b.
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increases as the severity of neoplasia and its clinical
stage also increases [29,30]. Sarcoid is considered as a
“benign” non metastatising tumour. In this regard, it is
reasonable to speculate that the reduction and/or
absence of MGMT in sarcoids may be correlated to their
relative benign biological behavior [1,4].
The presence of a functional MGMT gene is essential
to avoid occurring mutations in other important genes
involved in cancerogenic processeses. The silencing of
MGMT gene induces a mutator pathway affecting some
oncogenes such as Ras [31]. It is worth noting that sar-
coid tumours and sarcoid derived cell lines show an up-
regulation of Ras activity (Altamura et al., manuscript in
preparation). It is therefore possible to hypothesize a link
between MGMT down-regulation and Ras constitutive
activation. However, further investigations are needed to
confirm this, which is at moment only a matter of
speculation.
As previously observed for the FHIT protein, EqSO4b
cells revealed lower MGMT expression in comparison to
EqSO1a. MGMT reduced expression in vitro has been
linked to its binding to HPV E6 oncoprotein which is
able to enhance the ubiquitin-dependent proteolysis of
this oncosuppressor [13]. Additionally, HPV-16 E7 is
able to modulate the DNA methylation activity [32].
Since the EqSO4b cell line contains higher copy num-
bers of viral genome and oncoprotein transcripts than
the EqSO1a [33], it is possible that the observed
decreased level of MGMT protein found may directly
correlate with BPV oncogene expression levels and be
due to a similar mechanisms induced by BPV E5/E7
oncoproteins. Further studies are needed to elucidate
the molecular mechanisms underlying this peculiar
aspect.
Promoter methylation is the primary epigenetic alter-
ation associated with transcriptional silencing of tumour
suppressor genes during tumourigenesis [34-36]. To de-
termine if DNA methylation was involved in altered
MGMT expression in sarcoid tumours, we performed
the sodium bisulfite sequencing analysis of the CpG is-
land associated to the 50 untranslated region of MGMT
[37]. Our data indicated that in MGMT gene promoter
heavy hypermethylation occurred in 1 out of the 10 ana-
lyzed sarcoid samples and in EqSO4b cells. The sarcoid
sample and the EqSO4b cell line showed an overall similar
hypermethylation pattern. Differences may be explained
by the presence of some polymorphisms, a fortiori consid-
ering that the analysis was carried out for a not trans-
lated region. EqSO4b is a primary culture cell line and
this may introduce some difference too. Moreover it’s
to be considered that the region is very complex in its
sequence structure and this may promote polymerase
slippage.Similar frequency of MGMT hypermethylation is
observed in HPV induced cervical cancer [38], thus
supporting the hypothesis that MGMT promoter methy-
lation is not a common feature of PVs induced tumours.
Our findings indicate an association between BPV
infection and MGMT protein expression alteration
suggesting the possibility of a mechanistic role for this
gene as a cofactor triggering the development of equine
sarcoid tumour in concert with BPV.Conclusions
The biochemical, immunohistochemical and immuno-
fluorescence analyses suggest that MGMT protein is
reduced or absent in sarcoid tissues and sarcoid derived
cell lines. The epigenetic analysis suggests DNA methy-
lation as one of the possible causative mechanisms for
the loss of expression of MGMT in this tumour. Further
studies will be useful to confirm these findings and to
clarify the other mechanisms underlying MGMT alter-
ation in sarcoid carcinogenesis, but this study represents
the first example in veterinary oncology of the epigenetic
inactivation of the MGMT oncosuppressor.Methods
Tumour samples
Samples of equine sarcoid and normal skin from healthy
horse (N°15) were derived from the archives of the De-
partment of Pathology and Animal Health, University of
Naples “Federico II”. Sections taken from paraffin blocks
were stained by haematoxylin and eosin (HE) and re-
evaluated to confirm the diagnosis. Histologically, the
samples were characterized by epidermal hyperplasia
with rete peg invading the dermal tissue beneath. A dif-
fuse proliferation of dermal fibroblasts arranged in
whorls and or bundles was seen. A storiform pattern
was also recorded. All the tumour samples were diag-
nosed as equine sarcoids.
The samples were derived from different animals. All
sarcoids were known to be positive for BPV DNA
(Borzacchiello et al., 2008).
Five out of 15 sarcoids were immediately frozen at
−80°C and available for biochemical analysis.Cell cultures
E-Derm fibroblast cell lines, derived from horse dermis,
were obtained from the American Type Culture Collec-
tion. EqSO1a and EqSO4b have been described previ-
ously (Yuan et al., 2008). All cells were maintained in
culture in DMEM (Dulbecco's modified eagle medium)
supplemented with 10% FBS (Gibco) in a 37°C humidi-
fied atmosphere of 5% CO2 in air.
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Ten sarcoid samples and 1 skin sample were stained. A sec-
tion from a normal human tonsil was included as positive
control [39]. Briefly, paraffin sections were deparaffinized,
and blocked for endogenous peroxidase in 0.3% H2O2 in
methanol for 20 min. Antigen enhancement was performed
by pretreating with microwave heating (twice for 5 min
each at 525 W). The anti-MGMT antibody (Resnova,
Rome, Italy) was applied at 1:50 dilution overnight at room
temperature in a humified chamber. The slides were
washed three times with phosphate-buffered saline (PBS),
then incubated for 30 min with the appropriate biotinylated
secondary antibody (labelledstreptavidin–biotin (LSAB)
Kit; DakoCytomation, Denmark) as previously reported
(Borzacchiello et al., 2006 Oncogene). Sections were
washed three times with PBS and then incubated
with streptavidin-conjugated to horseradish peroxidase
(LSAB Kit; DakoCytomation, Denmark). Colour develop-
ment was obtained by treatment with diaminobenzidine
(DakoCytomation, Denmark) for 5 min. Sections were
counterstained with Mayer’s haematoxylin. In the corres-
ponding negative control section, the primary antibody was
either omitted or replaced with appropriate normal serum.
The scoring of the immunoreactivity was determined
in a ‘blind’ study by two observers (GB and AC). The
intensity of labelling in each specimen was scored from
absent to very strong immunosignal.
Immunofluorescence and confocal laser-scanning
microscopy
E-Derm, EqSO1a and EqSO4b cell lines were grown for
2 days on coverslips, washed with PBS, fixed in 4%
paraformaldehyde for 20 min, permeabilized with 0,1%
triton X-100 in PBS 5 min. The slides were blocked
with 2% BSA for 30 min. The anti-MGMT primary
antibody was applied O/N at 4°C in a humified chamber
at 1:50 dilution and after washing with PBS, incubated
with Alexa Fluor 488 goat anti-rabbit 30 min at RT
(Molecular Probes. Leiden, The Netherlands).
Finally, after washing with PBS, the slides were
mounted in aqueous medium PBS: Glycerol 1:1 (Sigma,
Milan, Italy). For scanning and photography, a confocal
laser-scanning microscope LSM-510 (Zeiss, Gottingen,
Germany) was used. The lambda of the argon ion laser
was set at 488 nm, and fluorescence emission was
revealed by BP 505–530 nm band pass filter.
Protein extraction and SDS PAGE/western blotting
Five sarcoids (S1;S2;S3;S4;S5) and one sample of normal
skin (N) were available for molecular analysis. These were
snap frozen in liquid nitrogen and homogenized in ice-
cold lysis buffer (50mM Tris pH7.5; 150mM NaCl; 1mM
EDTA; 0.25% Deoxicolic acid, 1% Triton X100) added
with 20 mM sodium pyrophosphate, 0.1 mg/ml aprotinin,2 mM phenylmethylsulphony fluoride (PMSF), 10 mM
sodium orthovanadate (Na2VO3), and 50 mM NaF.
Cell lines were grown for 2 days in 60-mm dishes,
washed with ice-cold phosphate saline buffer two times
and lysed for 20 minutes in ice-cold lysis buffer. Tissue
homogenates and cell lysates were clarified by centrifu-
gation, and the quantity of proteins was determined by
use of a protein assay kit (Bio-Rad Laboratories, Milan,
Italy). 50 μg of total protein were boiled and fractionated
in 15% SDS-PAGE gel. The proteins were blotted from
the gel onto nitrocellulose membranes. The membranes
were blocked with 5% non-fat dry milk in TBS buffer at
room temperature, washed with TBS–0.1% Tween and
incubated with anti-MGMT antibody at dilution 1: 500.
After appropriate washing steps, peroxidase-conjugated
anti-rabbit IgG (Amersham Pharmacia Biotech) were ap-
plied for 1 hour at 1:5,000. After washing, bound anti-
body was visualized on ECL film (Amersham Pharmacia
Biotech). The blots were stripped and reprobed against
mouse anti-actin antibody (Calbiochem) at 1:5,000 to
confirm equal loading of proteins in each lane.
Bioinformatic web tools for sequence analyses
and primer design
NCBI Genbank (http://www.ncbi.nlm.nih.gov/sites/entrez)
to obtain gene specific sequences; UCSC BLAT (http://
genome.ucsc.edu/cgi-bin/hgBlat) to obtain the sequence
of non-coding regions and to recovery and compare the
sequences of different species. BLASTalgorithm (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) to identify the more informative
sequences, to compare the horse specific nucleotidic
sequences with that of other species; Primer3plus (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.
cgi) and NCBI primer-blast (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/index.cgi) to design PCR pri-
mers; EMBOSS CpGPlot/CpGReport/Isochore (http://
www.ebi.ac.uk/Tools/emboss/cpgplot/) for the analysis of
the CpG content.
Cell line DNA extraction and CpG island gap sequencing
Genomic DNA was extracted from one 60-mm dish
respectively of E-Derm, EqSO1a and EqSO4b cell lines
according to the Wizard Genomic DNA Purification
Kit protocol (Promega, corporation, USA). The purified
DNA was resuspended in TE.
The lacking sequence of the equine specific MGMT
CpG island was obtained by PCR amplification using as
template E-Derm genomic DNA. The primers were
designed referring to the 50 MGMT sequence annotated in
UCSC sequence. The primer sequences are: MGMTgapF
50-GAGGCAACCCAGACACTCAC-30 and MGMTgapR
50-CAGGACAGCCAGCGAGAC-30. The purified PCR
product (535 bp) was directly sequenced by the dye termin-
ator method (PRIMM Facility, Naples, Italy). The sequence
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was submitted to GenBank JX390728].DNA extraction from paraffin-embedded sarcoid samples,
sodium bisulfite conversion and sequencing
Genomic DNA was isolated from paraffin-embedded
sections using standard procedures (Strazzullo et al., 2003)
and was precipitated with 250 mM NaCl and isopropa-
nol. DNA extracted from paraffin embedded samples and
cell lines (0.25 – 1 μg) was sodium bisulfite-converted
using the EpiTect Bisulfite Kit (Qiagen, Germany), accord-
ing to the protocol relative to the paraffin embedded
samples. Samples were eluted in a final volume of 20 μl
of elution buffer. To study the differential methylation
status of MGMT putative promoter, bisulfite sequen-
cing was performed. Briefly, 1 μl of sodium bisulfite-
converted DNA was amplified using a double step PCR
(semi-nested PCR) carried out using Gradient PCR
Express (Hybaid, Middlesex, UK). The step 1 primer
sequences are: MGMTbisF 50-GAGGGAGGTAATTTA
GATATTTAT-30 and MGMTbisR2 50-AAAAAACCTA
CAATAACAACAAC-30; the step 2 primer sequences
are: MGMTbisF and MGMTbisR2 50-CACAAACAAA
CAAAAAAACCC-30. The second amplification was car-
ried out using 1 μl of first amplification product as tem-
plate. The thermal cycling conditions were: 95°C for 3
min, followed by 95°C for 30 sec, 52°C for 45 sec and
72°C for 45 sec for 25 (first amplification) or 35
(second amplification) cycles. The product of the first
amplification was of 628 bp; the second product was of
572 bp. After amplification, PCR products were recovered
from agarose gel using QIAquick Gel Extraction Kit
(Qiagen), following manufacturer’s instructions. Purified
PCR products were cloned in the pGEMTeasy cloning
vector (Promega corporation, USA). After cloning, DNA
fragments were sequenced by the dye terminator method
(PRIMM Facility, Naples, Italy).Competing interests
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